Bayer Satellite Symposium

ISTH 2017 Congress | Berlin Germany

Sunday, July 9th | 14:15-15:45 |  Room: A7, Level 1, CityCube

Innovating for improved outcomes: Driving the evolution of hemophilia A management

Join our expert faculty to consider the future of hemophilia care and how we can use innovations in treatment to best meet the needs of our patients.

Chair: Robert Klamroth (Vivantes Hospital, Berlin, Germany)


Time for change? Plotting
a new course to optimal patient care

Realizing the potential of rFVIII therapy



From innovation to

real-life protection: The role for Kovaltry® in patients of all ages


Pursuing innovation in hemophilia A: Bayer’s commitment to the future


Robert Klamroth

(Vivantes Hospital, Berlin, Germany)


Alfonso Iorio

(McMaster University, Hamilton, Ontario, Canada)


Maria Elisa Mancuso

(Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Milan, Italy)


Lisa Michaels

(Bayer, USA)

BAYER, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer. © Bayer. May 2017 | G.MKT.SM.HEM.07.2017.1470 | L.DE.MKT.SM.07.2017.5807

If you would like to attend this satellite symposium, please select one of the options to receive
a calendar invite.


Google calendar

This medicinal product is subject to additional monitoring. Adverse events should be reported. Please report any suspected adverse reaction to your national authority. Please use the following website to find contact details of your respective local health authority: Name of the medicinal product: Kovaltry 250 / 500 / 1000 / 2000 / 3000 IU powder and solvent for solution for injection (Refer to full SmPC before prescription.) Composition: Each vial contains nominally 250/500/1000/2000/3000 IU human coagulation factor VIII. Excipients: Sucrose, histidine, glycine, sodium chloride, calcium chloride and polysorbate 80. Indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Known allergic reactions to mouse or hamster proteins. Warnings and Precautions: Allergic type hypersensitivity reactions are possible. The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. Haemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-haemophilic patients when clotting has been normalised by treatment with FVIII. If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bactaeremia and catheter site thrombosis should be considered. Undesirable effects: common: lymphadenopathy, palpitation, sinus tachycardia, abdominal pain, abdominal discomfort, dyspepsia, pyrexia, chest discomfort, injection site reactions (incl. injection site extravasation, hematoma, infusion site pain, pruritus, swelling), headache, dizziness, insomnia, pruritus, rash (rash, rash erythematous, rash pruritic), dermatitis allergic; uncommon: hypersensitivity, dysgeusia, urticaria, flushing. On prescription only. Marketing Authorisation Holder:
Bayer AG, 51368 Leverkusen, Germany. Date of revision of the underlying Prescribing Information: 04/2017.